Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind trial of RDEA806 versus efavirenz in antiretroviral-naive HIV-1 infected subjects
2008-005113-21Phase 2Terminated
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RDEA806 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Ardea Biosciences, Inc. Primary endpoint: Antiviral activity at 24 weeks. Started Sep 2008; status: terminated.
02
Drugs
RDEA806
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-005113-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005113-21.